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INTRODUCTION:  This  case  report  intends  to highlight  the  Haemodialysis  Reliable  Outﬂow  (HeRO)  graft  as
a potential  long  term  option  for ongoing  dialysis  in  patients  with  central  venous  stenosis.
PRESENTATION  OF  CASE:  A  55  year  old  patient,  who  developed  end  stage  renal  failure (ESRF)  after
chemotherapy  treatment  for  breast  cancer,  presented  at the  limit  of her dialysis  access  after  a 15 year
haemodialysis  history  causing  central  vein  stenosis.
The  patient  was  initially  started  on peritoneal  dialysis  but after repeated  peritonitis  was  switched  to
haemodialysis.
Over ﬁfteen  years  of haemodialysis  the patient  had  ﬁstulae  created  in all four  limbs.  She had  multiple
tunnelled  neck  lines  and  developed  an occluded  left brachiocephalic  vein  and stenosed  superior  vena  cava.
Catheter  dialysis  via  the  right  internal  jugular  vein  was  attempted  but  proved  increasingly  problematic
due  to poor  clearances  and  frequent  catheter  changes.
A  further  attempt  was  made  to  treat  with  peritoneal  dialysis,  but  again,  this  was  unsuccessful.
As  the  patient  had  two failed  attempts  at peritoneal  dialysis,  had  exhausted  all  her  peripheral  access
options,  and was  having  problematic  catheter  dialysis,  she  was  offered  the option  of  the HeRO  graft  as  a
‘last resort’.
DISCUSSION:  The  HeRO  graft  is  a fully  subcutaneous  vascular  access  system  that  bypasses  the  central
venous  system  providing  haemodialysis  access  for  patients  with  central  venous  stenosis.  It  consists  of an
arterial  graft  component  and  a venous  outﬂow  component,  which  are  connected  via a titanium  connector.
The  central  vein  stenosis/occlusion  is  stented  with  insertion  of the  graft  in to the  right atrium,  which  is
then  secured  to the  arterial  component  for  needling.  So  that  successful  dialysis  could  be  completed  as  soon
as possible  post-operatively,  the  HeRO  graft,  in  this  instance,  was  combined  with  an  immediate  needling
graft  (Acuseal).  This allowed  the  patient  to receive  successful  dialysis  within  hours  of  completing  the
procedure.
CONCLUSION:  This  patient  had  reached  the  end  of her haemodialysis  life  with  no other  options  available.
She  was  treated  successfully  with  the  HeRO  graft,  which  at two months  was  patent  and  problem  free.
The  patient  had  been  able  to return  to work  for  the  ﬁrst time  in  15  months.
Utilising the  HeRO  graft  in this  way  may  provide  new,  potentially  long  term,  options  for  safe  and
effective  dialysis  in  patients  with  central  venous  stenosis.
©  2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Central venous stenosis or occlusion is a very common prob-
em associated with haemodialysis in patients with end stage renal
ailure (ESRF) [1]. Unfortunately, the loss of central vascular access
orrelates with a reduced life expectancy. The development of
Abbreviations: HeRO, haemodialysis reliable outﬂow graft; ESRF, end stage renal
ailure; AV, arteriovenous; FDA, Food and Drug Administration; TDC, tunnelled dial-
sis catheter.
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central venous stenosis ultimately results in arteriovenous (AV)
haemodialysis vascular access being lost and prevents the creation
of new vascular access on the affected side.
Currently, guidelines recommend that all patients with ESRF
who start haemodialysis should do so with an AV ﬁstula in the ﬁrst
instance, an AV graft as second choice, a tunnelled venous catheter
as a third option and ﬁnally, a non-tunnelled temporary catheter
as an option of necessity only. Currently, there is no recommended
option if all of the above fail, as happened to the patient in this case
report.
The Haemodialysis Reliable Outﬂow (HeRO) graft is a fully sub-
cutaneous vascular access system that bypasses the central venous
system and so, is ideal for patients who have come to the end of
their haemodialysis life span due to central venous stenosis. The
graft aims to provide reliable, continuous blood ﬂow directly from
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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 target artery to the heart. Although classiﬁed by the Food and Drug
dministration (FDA) as a graft, the HeRO differs from convention
n that it has no venous anastomosis [2]. Instead, it consists of a
enous outﬂow component connected (via a titanium connector)
o an arterial graft component.
This case report intends to highlight the use of the HeRO graft as
 further, or fourth, option in haemodialysis provision in patients
ith central venous stenosis and terminal access options.
. Presentation of case
The patient was a 55 year old female who presented with ESRF
ollowing chemotherapy treatment for left-sided breast cancer. She
ad no other signiﬁcant medical history.
The patient was initially started on peritoneal dialysis but suf-
ered with repeated peritonitis and as such, was switched to
aemodialysis. She was treated for 15 years using a combination of
rteriovenous ﬁstulas, grafts and ﬁnally central catheters. All four
imbs were used during this time and multiple tunnelled neck lines
ited. Ultimately, the patient developed occlusion of the left bra-
hiocephalic vein and stenosis of the superior vena cava. Catheter
ialysis via the right internal jugular vein was then attempted but
roved problematic. Poor clearances and frequent catheter changes
rompted a further, unsuccessful attempt to treat with peritoneal
ialysis. In light of the patient’s ever dwindling options, it was at
his time that the patient was offered treatment with the HeRO
raft as a last resort. Understandably, the patient agreed.
The HeRO graft was placed under general anaesthesia utilising
ercutaneous endovascular techniques. The venous outﬂow com-
onent of the graft was placed in the mid  to upper right atrium
ia the right internal jugular vein using a standard Seldinger tech-
ique. The distal tip of the outﬂow component is placed so that
t sits just beyond the cava-atrial junction. The arterial graft com-
onent is then tunnelled along the upper arm and the titanium
onnector on the end of the graft joined to the venous outﬂow com-
onent at the deltopectoral groove. The graft is then anastomosed
o the brachial artery to complete the procedure. In order that the
atient received successful haemodialysis as soon as possible, this
ew technology was combined with an immediate needling graft
an Acuseal). The patient received haemodialysis within hours of
ompleting the procedure.
. Discussion
The number of patients with end stage renal failure (ESRF) is
ncreasing. The number of dialysis patients outliving their arteri-
venous (AV) access is also increasing [3]. As such, clinicians are
resented with the challenge of providing these patients with alter-
ative, deﬁnitive AV access for ongoing, successful haemodialysis
4].
A particularly common cause of AV access failure is central
enous occlusion and/or stenosis, with this reported in over 50%
f all haemodialysis patients [1,3].
Historically, patients who have had failed AV ﬁstulas and grafts
ave been offered tunnelled dialysis catheters (TDCs) [5]. How-
ver, TDCs are associated with high incidences of bacteraemia, poor
atency and reduced blood ﬂow rates and ultimately, increased
orbidity and mortality [6]. Katzman et al. report a TDC bacter-
emia rate of 2.3 per 1000 days and primary patency at 12 months
deﬁned as the interval from the time of access placement until any
ntervention) of just 36% [7]. For this reason, they are only consid-
red once all other options have been exhausted. They are currently
he option of last resort.
With the development of the HeRO graft, patients that had oth-
rwise exhausted their AV access and were either being consideredPEN  ACCESS
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for a catheter or were already catheter dependent, an alternative
for successful haemodialysis may be available. The HeRO graft may
potentially provide long term, deﬁnitive access in an extremely
challenging and complex group of patients.
A review of the literature highlighted that the HeRO graft, since
its approval by the FDA in 2008, has been offered to patients with
no option for further AV access and who are catheter dependent.
In this case report, the patient had not only exhausted all options
for AV access, including in the lower limbs, but had also attempted
multiple catheters as well as peritoneal dialysis more than once. It
is this type of patient that has presented clinicians with an almost
impossibility—the surgical creation of further deﬁnitive vascular
access in a population who have exhausted all other options.
Although only recently introduced for use in Europe, early stud-
ies suggest that the rate of complications associated with the HeRO
graft are signiﬁcantly less than those associated with the tunnelled
dialysis catheter (TDC) [3–5]. A review of the literature suggests
that rates of infection and bacteraemia associated with the HeRO
graft are signiﬁcantly less than those associated with TDCs and
consequently, the rates of associated mortality are also less. A sys-
tematic review of the literature by Al Shakarchi et al. report device
related bacteraemia (per 1000 days) of 0.13-0.7 and HeRO graft
infection in just 10.1% (2.5–21%) [4]. When compared with the
reported catheter-related incidences, it is evident that these values
are signiﬁcantly lower for the HeRO graft than they are for TDCs.
This is in part due to the fact that the device is entirely subcuta-
neous and there is no external component to increase the risk of
infection, as there is with the TDC [2].
As well as decreased infection rates, the HeRO graft also provides
superior patency compared to TDCs, with results proving similar to
those of the traditional AV grafts. Katzman et al. report primary
patency rates of 38.9% for the HeRO device, with direct comparison
to AV graft patency at 12 months of 42% [7]. Review of the literature
by Al Shakarchi et al. showed a range of patency rates for the HeRO
device of between 9.6% and 37.2% [4].
Other complications associated with TDCs such as thrombo-
sis, steal syndrome and ultimately, central venous stenosis and/or
occlusion have also been reported to be signiﬁcantly less for the
HeRO graft [4,6,7]. Both Al Shakarchi et al. and Katzman et al. noted
low incidences of steal syndrome with percentages reported as 6.3%
and 2.6% respectively [4,7].
The evidence currently available suggests that the HeRO graft
is an invaluable, if not lifesaving, option for access–challenged
patients and may  provide a deﬁnitive and effective treatment for
central venous stenosis [8].
4. Conclusion
Central venous stenosis is a devastating and often unavoidable
consequence of long-term haemodialysis with very few options
available to those patients affected by it. The HeRO graft may well
provide an effective treatment for those patients who are out of
options. As in this case report, the HeRO graft could be offered to
patients who  have reached the limit of their haemodialysis lifespan
and are, for all intents and purposes, terminal.
This relatively new technology has opened the door to poten-
tially long term options for safe and effective haemodialysis in
patients with central venous stenosis and will no doubt revolu-
tionise the lives of patients who have exhausted all other options
and are reaching the end of their haemodialysis life.Conﬂict of interest
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